EQUITY ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages DISH Network Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – DISH

NEW YORK, March 26, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of DISH Network Corporation (NASDAQ: DISH) between February 22, 2021 and February 27, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 22, 2023.

SO WHAT: If you purchased DISH securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the DISH class action, go to https://rosenlegal.com/submit-form/?case_id=13586 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 22, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company overstated its operational efficiency and maintained a deficient cybersecurity and information technology infrastructure; (2) as a result of the foregoing, the Company was unable to properly secure customer data, leaving it vulnerable to access by malicious third parties; (3) the foregoing cybersecurity deficiencies also both rendered Dish’s operations susceptible to widespread service outages and hindered the Company’s ability to respond to such outages; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DISH class action, go to https://rosenlegal.com/submit-form/?case_id=13586 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8795208

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CRBU

NEW YORK, March 26, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or traceable to the offering documents and related prospectus issued in connection with the Company’s 2021 initial public offering conducted on or about July 23, 2021 (the “IPO” or “Offering”); and/or (ii) between July 23, 2021 and December 9, 2022, both dates inclusive (the “Class Period”), of the important April 11, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Caribou class action, go to https://rosenlegal.com/submit-form/?case_id=11988 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 11, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Offering documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Offering documents and defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) CB-010’s treatment effect was not as durable as defendants had led investors to believe; (2) accordingly, CB-010’s clinical and commercial prospects were overstated; and (3) as a result, the Offering documents and defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

To join the Caribou class action, go to https://rosenlegal.com/submit-form/?case_id=11988 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8795186

“The ReStart Art Club” Private Party by Alia Al-Senussi and Dino Sadhwani Makes Triumphant Return to Hong Kong

The ReStart Art Club", the annual private party hosted by Princess Alia Al-Senussi and Dino Sadhwani during Art Basel Hong Kong returned this year after a hiatus due to the global pandemic and was held on Thursday, 23rd March 2023 at K11 ATELIER King's Road. This one-night only event brought together the global creative community and luminaries from different disciplines across regions to celebrate the reinvigoration of the international art scene in Hong Kong.

Hosts & Host Chairs of "The ReStart Art Club"

(From Left) Michael Govan, Eva Chow, Adrian Cheng, Dino Sadhwani, Princess Alia Al-Senussi, Philip Tinari & Alan Lau

Curated by Jason Swamy and produced by COI Communications, the theme of this year was an exploration of the binaries of art - familiar and foreign, digital and analog, acoustic and electronic, while showcasing the confluence of age, ethnicities, and cultures.

To highlight the concept of dualisms, the event was chosen to be held at K11 ATELIER King's Road, a contemporary office space with a vertical creative city concept, while the set paid homage to the industrial heritage of the area.

Art Basel Hong Kong's largest private event honoring movers and shakers of the art world returns

Alongside the hosts, this event was brought together by 5 distinguished Host Chairs: Adrian Cheng of K11 Group, Alan Lau of M+, Eva Chow of LACMA, along with Michael Govan of LACMA and Philip Tinari of UCCA, both of whom have participated in previous editions of the event, as well as 18 esteemed Host Committee members from around the region.

Celebrating arts, culture, and creativity in all shapes and forms

As guests arrived the venue, they were instantly met with a blend of cultures through a Chinese music performance with a modern twist, where musicians performed amidst an elevated stage full of larger-than-life flowers, and dancers dressed in matching colored body suits were concealed within the installation and emerged to greet and interact with guests.

Tying in the themes of nature and dualities, guests were then invited to enjoy a Five Flower Tea infused gin cocktail before traversing through the depths of nature at the digital exhibit created by d'strict at ARTE M Hong Kong, which is the first ever overseas showcase of Korea's largest immersive media art exhibition. In the future, ARTE M Hong Kong will move to 11 SKIES, Hong Kong's largest retailtainment new landmark, with more works added to the collection in a larger space with F&B facilities as a permanent exhibition.

Guests were then offered a molecular sphere cocktail and guided into a lift with an eccentric dance performance to continue their journey. The lift opened into an unrefined yet mysterious speakeasy decorated with traditional Hong Kong and industrial elements where spectacular performances were unveiled sequentially.

An endless night of enthralling performances from award-winning virtuosos

The 2023 edition saw over 8 local and international acts which were flown in from Ukraine, Switzerland, United States, Mexico, France, Philippines, Taiwan and more. One of the highlights of the evening at The Amber Room was an enthralling set by Sly5thAve, a Grammy-award winning musician. A dramatic curtain reveal marked the beginning of a high energy dance performance at The Green Room, followed by a riveting solo performance by accordion player Mario Batkovic, and DJ and dance performances that continued throughout the night.

A range of canapés inspired by local flavors and the Hong Kong dim sum culture were offered to guests to pay homage to our vibrant city, and beverages were sponsored by Two Moons Distillery, Moët & Chandon, Don Julio 1942, and KHEE Soju. Within the speakeasy, there was also a dragon-i branded lounge area, which served as a forerunner to the after-party that continued at the club.

Other contributing artists at the event included Min Joon Lee, the international collective Hyper Futurism with a curation of digital artworks, and Magic Room with a selection of Hong Kong-styled neon signs.

The hosts, Princess Alia Al-Senussi and Dino Sadhwani, have successfully created yet another captivating, fun-filled event and captured the spirit of reconnecting and restarting. The party lived up to the hype from its previous editions and will certainly be remembered as a must go-to event in the calendar during Art month in Hong Kong. It is hoped that the event will continue the success in celebrating the collaboration among people passionate about art and culture, performance, gastronomy, music and entertainment.

Sponsors: 11 SKIES, d'strict, Moët & Chandon, Don Julio, Cloudy Bay, KHEE Soju, Two Moons Distillery

Hosts: Princess Alia Al-Senussi and Dino Sadhwani

Host Chairs & Host Committee Members who attended: Adrian Cheng, Alan Lau, Eva Chow, Michael Govan, Philip Tinari, Alan Lo and Yenn Wong, Alison Chan, Claudine Ying, Edward Tang, Eugene Tang, Gilbert and Martina Yeung, Ivan Pun (Myanmar), James Neary, Jonathan Cheung, Katrina Razon (Philippines), Lester Lam, Loui Lim, Marc Spiegler (Switzerland), Pranitan (Pete) Phornprapha (Thailand) and Rishabh Tongya (India)

Some notable guests from the art world include: Sir David Adjaye, Cecile Debray, Marc Spiegler, Kyoko Hattori, Vassilis Oikonomopoulos, Marisa Chearavanont, Lim Se-Ryung, Beeple, Staffan Ahrenberg, Simon De Pury, Sean Lee, and Aaron Cezar

Some notable guests from the fashion and entertainment world include: Tina Leung, Lisa Haydon, Georgina Wilson, Kelly Cheung, Serrini, Fiona Xie, Sarah Song

Some of the local prominent guests include: Bruce Rockowitz, Sonia Cheng, Kevin Poon, Rigel Davis, Karim El Azar, Marisa Yiu, Sonia Cheng, Antonia Li, Feiping Chang, Emily Lam, Elly Lam & Victoria Tang

About Hosts

About Princess Alia Al-Senussi

Princess Alia Al-Senussi, PhD, is an active member of the contemporary art world with a focus on cultural strategy and patronage systems. She is a cultural strategist, writer, patron, public speaker and academic.

Princess Alia has served as Art Basel's UK and MENA Representative for over a decade, and is also currently Senior Advisor, International Outreach for Art Basel. In 2019 she was appointed Senior Advisor to the Ministry of Culture, Saudi Arabia, where she focuses on developing international partnerships whilst working on a variety of projects across the Ministry's commissions and the Diriyah Biennale Foundation. Princess Alia is a visiting lecturer at Brown University's Watson Institute, working with the Middle East Studies Program.

Princess Alia is currently a member of the Tate Modern Advisory Council (London), the Strategic Advisory Panel of the Delfina Foundation (London), the Board of Trustees of The Showroom (London), the Board of Trustees of FUNTASIA/Elisa Sednaoui Foundation (UK / Egypt / Italy), the Board of Governors of Aiglon College (Switzerland) as well as a member of Therme Art Advisory Board (Germany) and the UCCA Contemporary Circle (China).

She continues to serve a0073 a founding member of the Tate's Acquisitions Committee for the Middle East and North Africa, the Board of 1:54 The African Art Fair, and the Middle East Circle of the Guggenheim, the Middle East Studies Advisory Committee at Brown University, the Serpentine Future Contemporaries (and founding committee member) as well as was a founding member of the Board of Patrons of Art Dubai, having played an integral role in the founding of the fair. Princess Alia is also a member of the British Museum committee for the acquisition of Middle Eastern art.

Dr Alia has a PhD in Politics from SOAS (London), examining the nexus of power and cultural patronage, featuring Saudi Arabia as a case study. She graduated Magna Cum Laude in International Relations (honors) and Middle East Studies from Brown University and holds an MA in Political Science from Brown and an MSc in Law, Anthropology and Society from the London School of Economics.

About Dino Sadhwani

Dino is a seasoned and passionate entrepreneur who brings decades of experience building successful ventures to the table. After attempting his first business at the age of fifteen and later moving to Los Angeles for university, Dino went on to launch, grow, and help lead multiple successful start-ups worldwide in the diverse realms of F&B, wellness, commodities, venture capital, and supply chain management. He is also the co-founder and host of one of the international art world's preeminent experiences: LACMA's annual Art Basel party in Hong Kong. A proud perfectionist with a skilled attention to detail, Dino has a proven gift for numbers and pattern recognition. He enjoys creating and growing efficient, foolproof systems that fuel transformation and enrich lives.

A dad who loves nothing more than spending time with his children, Dino winds down with a football at his feet or a racquet in his hand. He has an affinity for mathematics, psychology and philosophy, and orients his life around the energies of probability and potential.

Host Chairs

About Adrian Cheng

Adrian is the Chief Executive Officer (CEO) of New World Development, which spans property, infrastructure, construction, hotels and other consumer and technology businesses. Since joining the company in 2006, he has reinvented the brand's DNA through 'The Artisanal Movement', infusing craftsmanship, heritage, design and creativity into all of the company's ventures. In 2008, Adrian established the K11 brand, K11 Group, the world's first 'cultural-retail' concept, with the intention of merging art and commerce and curating the customer journey with a focus on the next generation. Envisioned as the 'Silicon Valley of Culture', K11 MUSEA is a world-class cultural retail destination in Hong Kong, which helps meet the growing consumer demand for immersive and unique experiences.

In 2010, Adrian founded the K11 Art Foundation, the first private, non-profit organization to support Chinese artists and curators. Further to this in 2018, Adrian founded the K11 Craft & Guild Foundation, in an effort to preserve and rejuvenate traditional and aging Chinese art. Adrian was awarded the Silver Bauhinia Star by the HKSAR government in 2022 for his outstanding contributions to Hong Kong. At the start of 2023, Adrian was appointed as the Chairman of the Mega Arts and Cultural Events Committee by the Hong Kong Government to strengthen the city's status as a cultural exchange hub between China and the rest of the world.

About Alan Lau

Alan Lau is Vice Chair of M+, Hong Kong's largest contemporary art museum. He is also Chairman of ParaSite, the longest standing non-profit local art space. He co-chairs the Asia Pacific Acquisition Committee of Tate, and the Asia Art Circle of Guggenheim. He has been a technologist for 20 years, with leadership roles in McKinsey and Tencent. Mr. Lau is currently CBO of Animoca Brands, a $6bn blockchain company building multiple open metaverses to mass-onboard Web2 users to Web3.

About Eva Chow

Eva Chow, also known as Eva Chun, began her creative endeavors at a young age training in Korean traditional watercolor. She later moved to the United States where she enrolled at the Otis Parsons School of Design and started her fashion career. With the international success from selling to Bergdorf, Barney's, Neiman Marcus, Saks Fifth Avenue, and more, Eva opened her flagship showroom in 550 Seventh Avenue in New York. She joined CFDA in 1991 and was touted as 'one of the top five young designers in America' by The New York Times. A favorite to celebrities like Nicole Kidman, Sharon Stone and Angelica Houston to name a few, many of her designs have also been photographed by eminent photographers like Helmut Newton and Herb Ritts, and have appeared in numerous issues of Vogue, Harper's Bazaar, as well as the cover of Vanity Fair and Women's Wear Daily. It was in New York where she met collector, designer and restaurateur, Michael Chow, and the pair married in 1992. Eva also serves on the Board of Trustees at Los Angeles County Museum (LACMA) where she has founded and co-chairs an annual 'Art + Film' gala with Leonardo DiCaprio since 2011, attended by guests from all over the world of art, film and fashion.

About Michael Govan

Michael Govan joined the Los Angeles County Museum of Art (LACMA) as Chief Executive Officer and Wallis Annenberg Director in 2006. In this role, he oversees all activities of the museum, from art programming to the expansion and upgrade of the museum's 20-acre campus. During his tenure, LACMA has acquired by donation or purchase more than 56,000 works for the permanent collection, doubled gallery space and programs, and more than doubled its average annual attendance to well over one million. Currently the museum is in the process of building a new, state-of-the-art permanent collection building designed by Pritzker Prize-winning architect Peter Zumthor.

About Philip Tinari

Philip Tinari is Director and Chief Executive of UCCA Center for Contemporary Art in Beijing. Since joining in 2011, he has led its transformation into China's leading independent contemporary art institution, with an annual audience of over one million visitors. Tinari was founding editor of the magazine LEAP, contributing editor of Artforum, co-curator of the 2017 exhibition "Art and China after 1989: Theater of the World" at the Guggenheim, and artistic director of the First Diriyah Biennale.

Institutions

About LACMA

Located on the Pacific Rim, LACMA is the largest art museum in the western United States, with a collection of more than 149,000 objects that illuminate 6,000 years of artistic expression across the globe. Committed to showcasing a multitude of art histories, LACMA exhibits and interprets works of art from new and unexpected points of view that are informed by the region's rich cultural heritage and diverse population. LACMA's spirit of experimentation is reflected in its work with artists, technologist, and thought leaders as well as in its regional, national, and global partnerships to share collections and programs, create pioneering initiatives, and engage new audiences.

https://www.lacma.org/

About UCCA

UCCA Center for Contemporary Art is China's leading contemporary art institution. Committed to bringing the best in art to a wider audience, UCCA shares a wide range of exhibitions, public programs, and research initiatives to a public of more than one million visitors each year across three locations. UCCA Beijing sits at the heart of the 798 Art District, occupying 10,000 square meters of factory chambers built in 1957 and regenerated in 2019 by OMA. UCCA Dune, designed by Open Architecture, lies beneath the sand in the seaside enclave of Aranya in Beidaihe. UCCA Edge, designed by New York-based architecture firm SO – IL, opened in Shanghai in May 2021. Formally accredited as a museum by the Beijing Cultural Bureau in 2018, UCCA also operates non-profit foundations, licensed by the Beijing Bureau of Civil Affairs and the Hong Kong government. UCCA's commercial ventures include the retail platform UCCA Store, the children's education initiative UCCA Kids, and collaborations and projects under the rubric UCCA Lab. Opened in 2007 and revived by a committed group of Chinese and international patrons in 2017, UCCA works to bring China into global dialogue through contemporary art.

https://ucca.org.cn/en

About K11 Art Foundation

Founded by Dr. Adrian Cheng in 2010, K11 Art Foundation is a non-profit organization in Hong Kong dedicated to fostering the development of Chinese contemporary art. In pursuing our mission, we are committed to supporting artists and young curators through K11 Art Foundation's exhibitions, artist residencies, and educational programmes. We also actively establish partnerships with leading art and cultural institutions around the world, collaborating with curators and other industry specialists to create impactful cross-cultural exchange and contribute to the expanding global contemporary art discourse.

Over the years, K11 Art Foundation has collaborated with the Royal Academy of Arts, Serpentine Galleries, and the Institute of Contemporary Arts, London; Centre Pompidou, Palais de Tokyo, and Musée Marmottan Monet, Paris; Fundació Gala-Salvador Dalí, Figueres; the Metropolitan Museum of Art, the New Museum, The Museum of Modern Art, and MoMA PS1, New York; Museum of Contemporary Art, Los Angeles; UCCA Center for Contemporary Art, in Beijing; and Videotage, British Council Hong Kong, Design Trust, and Asia Art Archive, Hong Kong, among others.

www.k11artfoundation.org

Working Partners

About Jason Swamy - Creative Director

Jason Swamy is a creative visionary and thought leader that has helped shape cultural zeitgeist through art, music, food, wellness, thought leadership and community building. He's best known for his involvement with the legendary Robot Heart, award winning Wonderfruit and critically acclaimed Further Future.

He is highly sought after globally for his creative, curation and experience design ability. He's a tastemaker that has influenced many. Always pushing boundaries, his work defies definition.

Swamy has worked with A-listers from tech leader Eric Schmidt, 3 Star Michelin Chef Gaggan, Grammy Winner Skrillex to award winning hotels like The Upper House, NASDAQ listed tech behemoth Netease and innovative casino group Melco Crown to name but a few.

About COI Communications - Producer

COI stands for Collection of Individuals – as they curate the best collection of talent from their core team, vendors, collaborators and clients - because they believe that a group of likeminded and determined individuals working together in tandem can create a force strong enough to break traditions, assumptions and expectations.

Based in Hong Kong, COI Communications is a boutique events and communications agency founded with a curious spirit and a specific objective: to offer businesses a new way to engage their audience in its most genuine, yet creative form.

COI does not believe in using the same formula for each project. This is why they surround themselves with talented crafters, eccentric creatives and disruptive thinkers to ensure that each project, no matter the size or scope is as unique and enjoyable to its end users as it has been for their team to create.

Source: Xinhua Finance Agency

Uni-Bio Science Group Limited Announces 2022 Annual Results

Record High Turnover of HK$440.3 Million and HK$38.5 Million Profit Achieved

Expanding Portfolio with New Drug Innovations and Strategic R&D Partnerships

HONG KONG SAR - EQS Newswire - 27 March 2023 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2022 (the "Year").

Key Accomplishments in 2022

During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:

During the Year, the Group achieved a record high turnover of HK$440.3 million, representing a noticeable increase of 24.6% year-on-year ("YoY"). Sales of Pinup® and Boshutai® performed exceptionally well, registering an increase of 51.2% and 292.5% YoY respectively.

The Group made a remarkable turnaround, posting a profit of HK$38.5 million with a significant increase of 296.6% YoY, marking an important milestone for a research-oriented biopharmaceutical company.

The Group's Acarbose Tablets (Boshutai®) was successfully awarded the drug alliance procurement bid for the second and fourth batches of medicines for two years in the 13-provinces Alliance Procurement. To meet the growing demand for Boshutai®, the Group had already expanded its production capacity at its strategic partner's Suzhou production site to ensure supply stability.

New Drug Application ("NDA") of the Group's Bogutai® (teriparatide injection) had been accepted by the China National Medical Products Administration ("NMPA") and completed the China Center for Food and Drug Inspections ("CFDI") registration site verification. Bogutai® will be the Group's fifth marketed drug and the first domestically manufactured PTH Liquid in China to use a disposable injection pen.

The Group has continuously improved EGF process technology and increased the production capacity of the drug substance to 4 times the original amount, further enhancing production efficiency, reducing costs, while opening up new formulation opportunities.

The formulation development of oral form Uni-GLP-1 was completed, and the results showed that its bioavailability was superior to the positive control oral semaglutide. Currently, formal animal studies in beagle dogs are under preparation to further validate the bioavailability and pharmacokinetics of the oral form Uni-GLP-1 in animals. The clinical work of Uni-GLP-1 injection pen is on schedule for related pharmacological studies.

The Group's fibronectin products are shown to be as effective as natural fibronectin derived from human blood. During the Year, the Group had completed the development of fibronectin raw material, which have high yield and high activity. It will be the first advanced skincare raw material of the Group to be launched.

Annual Results

In 2022, the Group recorded a record-breaking revenue of approximately HK$440.3 million, representing a significant increase of 24.6% year-on-year (2021: HK$353.4 million). The increase in revenue was mainly attributable to the impressive sales growth of Pinup® and Boshutai®. Pinup® saw a remarkable increase of 51.2% in revenue, jumping from approximately HK$142.2 million to approximately HK$215.1 million for the Year. The increase was attributable to Pinup®'s inclusion in the national centralized procurement in 2021, which has secured the Group with substantial hospital orders. During the Year, revenue of Boshutai® increased substantially from approximately HK$4.5 million to approximately HK$17.4 million, representing a significant increase of 292.5%. GeneSoft® recorded an increase in revenue from approximately HK$36.3 million to approximately HK$38.4 million, representing an increase of 6.0%. Revenue generated from GeneTime® was approximately HK$169.4 million, representing a decrease of 0.6% from approximately HK$170.5 million in 2021. Despite the pandemic-related production interruptions in the first quarter of 2022, the Group quickly resumed and upgraded production of GeneTime®. As a result, sales of GeneTime® resumed growth in the second half of the Year, offsetting the earlier shortfall.

Gross profit was approximately HK$334.9 million, representing an increase of 20.9% as compared with approximately HK$277.0 million in 2021, whereas gross profit margin was 76.1% (2021: 78.4%). Thanks to the Group's diligent internal control, general and administrative expenses accounted for merely 10.7% of revenue in 2022 as compared with 13.3% in 2021. The selling and distribution expense for the Year also decreased to 48.0% of revenue from 52.5% in 2021. The R&D expenses decreased by 28.8% to approximately HK$35.8 million due to the completion of several clinical tests and the capitalization of development expenses.

The Group's commitment to cost control and profitability resulted in earnings before interest, tax, depreciation and amortization ("EBITDA") for the Year of HK$65.8 million as compared to HK$13.7 million in 2021. Net cash flow of HK$48.7 million from operating activities for the Year was recorded, representing the second consecutive year of positive cash flow for the Group. The Group recorded a profit of approximately HK$38.5 million for the Year, a remarkable increase of 296.6% year-on-year (2021: loss of HK$19.6 million). Basic earnings per share was approximately HK$0.61 cents (2021 basic loss per share HK$0.31 cents).

Prospects

Despite the reopening of borders, global economic headwinds are expected to continue in 2023 due to rising interest rates, inflation, and geopolitical trends. These factors will create economic shifts and challenges for businesses in areas such as trade, investment, and labor. Yet, with the implementation of the "Healthy China" strategy and the support of favorable factors such as supportive policies, industry efforts, and capital investments, the pharmaceutical and healthcare sector is expected to remain one of the most dynamic and promising fields in China over the longer term.

Despite the unpredictable headwinds, the Group has consistently maintained a healthy financial position with a positive cash flow and a manageable debt load. Our innovative "four-wheel drive" business model, which includes high-value generic drugs, bio-innovative drugs, new skincare raw materials, and CMO business, enables us to diversify our income streams and adapt to changing market conditions. This approach fosters sustainable growth while positioning us as a leader in the competitive biopharmaceutical landscape.

Looking forward, Mr. Kingsley Leung, Chairman of Uni-Bio Science said, "We are well-equipped to navigate challenges and capitalize on emerging opportunities, remaining dedicated to product innovations. We have enhanced production capacity four-fold to meet the growing demand of our signature EGF products. We have also been exploring different applications of the EGF products while developing different dosage forms of the EGF products, such as gel form, film form, and VSD foam dressings. The single-dose form of GeneSoft® (no preservatives) utilizing the Blowing Filling and Sealing packaging technology has also been under development, which can reduce the risk of cross-infection as well as is safer and more convenient to use. This technology will also be used to develop Diquafosol Sodium Eye Drops, which is complementary to GeneSoft®.

Besides product innovation, our product development has also come to fruition. Bogutai®, the first domestically manufacturing PTH Liquid in China to use a disposable injection pen, will be approved for product launch by September 2023. It will become our fifth marketed and self-developed drug. We believe that Bogutai® will become another signature product. Meanwhile, our first advanced raw skincare material, fibronectin, is also ready for market launch in 2023. We believe with these products will further diversify our revenue stream and will ride on the growing market opportunities. At the same time, we have been preparing for the new round of national centralized procurement for Pinup®, which will be launched as soon as in April 2023. As Pinup® was among the first to be selected in the fourth batch of the national centralized procurement, the Group will enjoy the advantage and is confident to be selected in the upcoming procurement.

Uni-Bio is steadfast in its efforts to strengthen its comprehensive R&D capabilities and broaden its portfolio of best-in-class products. We have been partnering with Alephoson Biopharmaceuticals Ltd. and DotBio Pte. Ltd. to investigate the potential application of Cell Penetration Protein Alternation Technology (CePPA) and co-develop next-generation best-in-class compounds in ophthalmology and other potential therapeutic areas since late 2021. We have also committed to the research of innovative delivery technology for oral drugs of peptide drugs to solve many pain points caused by traditional single drug delivery. Some of which under development include 3rd generation oral form of Uni-PTH, oral dosage form of Uni-GLP-1, as well as Uni-GLP-1 injection pen. Through these efforts, we aim to further diversify the formulation choices of the Group's marketed and future products, providing better solutions that meet the evolving needs of patients."

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development centre is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology.

Source: Xinhua Finance Agency

Caretaker CM KP directs to improve mechanism of provision of free flour to deserving families

Caretaker Chief Minister Khyber Pakhtunkhwa Muhammad Azam Khan has directed the concerned authorities to improve the mechanism of provision of free flour to the deserving and needy people in the province.

In a statement issued in Peshawar on Monday, he asked the District Administration officials to ensure their presence on ground during distribution of free flour across Khyber Pakhtunkhwa.

Muhammad Azam Khan stressed the need for proper monitoring of the process of free flour distribution so that the needy and poor families can get the flour.

The Chief Minister also directed for appropriate and effective planning to avoid any untoward incident.

Source: Radio Pakistan

Death anniversary of Sir Syed Ahmed Khan observed

The 125th death anniversary of great leader, scholar, Philosopher poet and educationist Sir Syed Ahmed Khan was observed on Monday.

Sir Syed is hailed as the father of the Two Nation Theory and one of the founding fathers of Pakistan, along with Allama Iqbal and Quaid-e-Azam Muhammad Ali Jinnah.

He was the founder of Aligarh movement which was the base of Pakistan movement.

His famous books included Khutbat-e-Ahmediya, Asbab-e-Baghawat-e-Hind, The Aligarh Institute Gazette and Tehzib-ul-Akhlaq".

He was conferred upon the title of Javad-ud Daulah and Arif Jang.

He died on this day in 1898 in Aligarh, India.

Source: Radio Pakistan